

Collagenofibrotic Glomerulopathy Confirmation, Mass Spectrometry

Overview

Useful For

Aiding in the diagnosis of collagenofibrotic glomerulopathy

Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
MLCPC	Microdissection, Laser	No, (Bill Only)	No
	Capture		
MSPTC	Mass Spectrometry	No, (Bill Only)	No

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

NY State Available

Yes

Specimen

Specimen Type

Special

Necessary Information

Preliminary pathology report, history, and electron microscopy images are required.

Specimen Required

Supplies: Pathology Packaging Kit (T554)

Specimen Type: Formalin-fixed, paraffin-embedded kidney tissue block

Collection Instructions: Do not send fixed tissue slides. Testing can only be done on paraffin-embedded tissue blocks.

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

- -Kidney Transplant Test Request
- -Renal Diagnostics Test Request (T830)

Reject Due To

Fixed tissue	Reject
slides	



Collagenofibrotic Glomerulopathy Confirmation, Mass Spectrometry

Wet/frozen
tissue
Cytological
smears
Nonformalin
fixed tissue
Nonparaffin
embedded
tissue

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Special	Ambient (preferred)		
	Refrigerated		
	Frozen		

Clinical & Interpretive

Clinical Information

Collagenofibrotic glomerulopathy (CG), also called collagen type III glomerulopathy, is a rare kidney disease characterized by large amounts of atypical type III collagen fibrils in the mesangium and subendothelial space of renal glomeruli. Liquid chromatography tandem mass spectrometry performed on microdissected glomeruli from patients with CG demonstrates a unique proteomic profile. The presence of type III collagen, in the appropriate clinical and pathological context, can be useful to establish a diagnosis of CG.

Reference Values

An interpretive report will be provided.

Interpretation

An interpretation will be provided.

Cautions

No significant cautionary statements

Clinical Reference

- 1. Chen X, Wan H, Xu W, Zhu J. Collagen type III glomerulopathy: Case report and review of the literature. Clin Nephrol. 2017;1:39-46
- 2. Dong J, Wei H, Han M, Guan Y, Wu Y, Li H. Collagen type III glomerulopathy: A case report and review of 20 cases. Exp Ther Med. 2015;10(4):1445-1449
- 3. Kurien AA, Larsen CP, Cossey N. Collagenofibrotic glomerulopathy. Clin Kidney J. 2015;8(5):543-547
- 4. Cohen AH. Collagen type III glomerulopathies. Adv Chronic Kidney Dis. 2012;19(2):101-106
- 5. Duggal R, Nada R, Rayat CS, Sakhuja V, Joshi K. Collagenofibrotic glomerulopathy a review. Clin Kidney J.



Collagenofibrotic Glomerulopathy Confirmation, Mass Spectrometry

2012;5(1):7-12

Performance

Method Description

Affected areas are removed from paraffin-embedded tissues by laser microdissection. Protein digestion is performed, followed by liquid chromatography tandem mass spectrometry. (Unpublished Mayo method)

PDF Report

No

Day(s) Performed

Monday through Friday

Report Available

7 to 15 days

Specimen Retention Time

Until reported

Performing Laboratory Location

Mayo Clinical Laboratories- Rochester Main Campus

Fees & Codes

Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82542

88380

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value



Collagenofibrotic Glomerulopathy Confirmation, Mass Spectrometry

MSCG	CG Confirm, LC MS	65757-7

Result ID	Test Result Name	Result LOINC® Value
615299	Interpretation	50595-8
615300	Participated in the Interpretation	No LOINC Needed
615301	Report electronically signed by	19139-5
615302	Material Received	81178-6
615303	Disclaimer	62364-5
615304	Case Number	80398-1
617019	Gross Description	22634-0
617020	Addendum	35265-8